Substituted pyrazolo piperidine carboxylic acids
Summary
USPTO granted patent US12595247B2 to Bayer Aktiengesellschaft covering substituted pyrazolo piperidine carboxylic acids, their salts, and processes for preparation. The patent includes 6 claims and lists 18 inventors. The compounds are directed toward cardiovascular and cardiac diseases, including heart failure with reduced, mid-range, and preserved ejection fraction.
What changed
USPTO granted patent US12595247B2 for substituted pyrazolo piperidine carboxylic acids to Bayer Aktiengesellschaft. The patent covers compounds useful for treating cardiovascular diseases, heart failure, hypertension, peripheral arterial diseases, chronic kidney disease, pulmonary hypertension, neurodegenerative diseases, and fibrotic diseases. The patent includes 6 claims and was granted with kind B2.
Pharmaceutical companies developing cardiovascular or renal drugs should assess freedom-to-operate to avoid infringing Bayer's newly granted patent claims. Generic or biosimilar manufacturers may explore licensing opportunities. Researchers studying the specified disease areas should consider the newly granted patent rights when designing studies or developing competing compounds.
What to do next
- Monitor for patent expiration dates and freedom-to-operate implications
- Review product development pipeline for potential infringement of granted claims
- Consider licensing opportunities for interested parties
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Substituted pyrazolo piperidine carboxylic acids
Grant US12595247B2 Kind: B2 Apr 07, 2026
Assignee
Bayer Aktiengesellschaft
Inventors
Alexandros Vakalopoulos, Marie-Pierre Collin-Kröpelin, Nuria Ortega Hernandez, Andre Dieskau, Melissa Boultadakis-Arapinis, Lisa Candish, Timo Stellfeld, Ilka Mathar, Lucas Hudson Hofmeister, Peter Sandner, Frank Wunder, Lisa Dietz, Robert Alan Webster, Carsten Schmeck, Thomas Mondritzki
Abstract
The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
CPC Classifications
C07D 401/14 C07D 401/04
Filing Date
2022-02-08
Application No.
17667410
Claims
6
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.